• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by TC BioPharm (Holdings) plc

    2/28/23 4:39:23 PM ET
    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TCBP alert in real time by email
    SC 13G 1 ea174442-13gnipro_tcbio.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    TC BioPharm (Holdings) plc
    (Name of Issuer)

     

    ADSs / Ordinary Shares
    (Title of Class of Securities)

     

    87807D202

    (CUSIP Number)

     

    Nipro Corporation

    Division of New Business Development

    9-3, Honjo-nishi 3-chome

    Kita-ku, Osaka

    531-8510 Japan

    Attention: Kimihito Minoura

    81-(0)6-6375-6703

     

    with a copy to:

     

    John P. Crutcher, Esq.

    Barton LLP

    711 Third Avenue, 14th Floor

    New York, New York 10017

    (212-885-8858)

    (Name, Address and Telephone Number of Persons Authorized
    to Receive Notices and Communications)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☐Rule 13d-1(c)

     

    ☒Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1.NAMES OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    NIPRO CORPORATION

     

     

    2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

    (a)   ☐

    (b)   ☐

     

     

    3.SEC USE ONLY

     

     

     

     

    4.CITIZENSHIP OR PLACE OF ORGANIZATION

     

    JAPAN

     

     

    5.SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON –

     

    38,6101

     

     

    6.SHARED VOTING POWER -

     

    -0-

     

     

    7.SOLE DISPOSITIVE POWER –

     

    38,6101

     

     

    8.SHARED DISPOSITIVE POWER -

     

    -0-

     

     

    9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON –

     

    38,610

     

     

    10.CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

     

     

     

    11.PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4%2

     

     

    12.TYPE OF REPORTING PERSON

     

    CO

     

     

     

    1Prior to the time of TC Biopharm (Holdings) Plc initial public offering (February 10, 2022), Nipro Corporation held 1,930,500 Ordinary Shares of TC BioPharm (Holdings) Plc, which, giving effect to the transactions inherent in the initial public offering, represented 7.3% of the outstanding Ordinary Shares. Subsequent to the initial public offering, TC BioPharm (Holdings) Plc has conducted additional issuances of Ordinary Shares and a reverse split recapitalization such that Nipro’s holdings as of January 12, 2023 are 38,610 Ordinary Shares representing 4% of the outstanding Ordinary Shares.

     

    2Based upon a total number of outstanding Ordinary Shares of 949,958 as reported by TC BioPharm (Holdings) Plc.

     

    2

     

     

    ITEM 1 (a) NAME OF ISSUER:

     

    TC BioPharm (Holdings) Plc

     

    ITEM 1 (b) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

     

    Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR Scotland, United Kingdom

     

    ITEM 2 (a) NAME OF PERSON FILING:

     

    Nipro Corporation

     

    ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

    9-3, Honjo-nishi 3-chome, Kita-ku, Osaka, 531-8510 Japan

     

    ITEM 2 (c) CITIZENSHIP:

     

    Japan

     

    ITEM 2 (d) TITLE OF CLASS OF SECURITIES:

     

    The class of equity securities to which this Schedule 13G relates are the ordinary shares, £0.0001 par value and ADSs related thereto (together, the “Ordinary Shares”) of TC BioPharm (Holdings) plc, a company formed in Scotland, under the Companies Act 2006 of the United Kingdom (the “Issuer”)

     

    ITEM 2 CUSIP NUMBER:

     

    87807D202

     

    ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

     

    (a) ☐ Broker or dealer registered under Section 15 of the Exchange Act.
    (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act.
    (c) ☐ Insurance Company defined in Section 3(a)(19) of the Exchange Act.
    (d) ☐ Investment Company registered under Section 8 of the Investment Company Act.
    (e) ☐ An Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E)
    (f) ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(ii)(F)
    (g) ☐ A parent holding company or control person in accordance Rule 13d-1(b)(1)(ii)(G)
    (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
    (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
    (j) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(J)

     

    3

     

     

    ITEM 4 OWNERSHIP:

     

    (a)AMOUNT BENEFICIALLY OWNED:

     

    38,610

     

    (b)PERCENT OF CLASS:

     

    4%

     

    (c)NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

     

    (i)SOLE POWER TO VOTE OR DIRECT THE VOTE

     

    38,610

     

    (ii)SHARED POWER TO VOTE OR DIRECT THE VOTE

     

    -0-

     

    (iii)SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    38,610

     

    (iv)SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    -0-

     

    ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    X  Nipro Corporation holds, as of the date of this Schedule 13G, less than 5% of the Issuer’s outstanding Ordinary Shares.

     

    ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    N/A

     

    ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

     

    N/A

     

    ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

     

    N/A

     

    ITEM 9   NOTICE OF DISSOLUTION OF GROUP

     

    N/A

     

    ITEM 10. CERTIFICATION.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect

     

    4

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 28, 2023
       
      /s/ Kimihito Minoura

     

     

    5

     

     

     

     

    Get the next $TCBP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCBP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TCBP
    SEC Filings

    See more
    • SEC Form 6-K filed by TC BioPharm (Holdings) plc

      6-K - TC BioPharm (Holdings) plc (0001872812) (Filer)

      3/21/25 11:22:27 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by TC BioPharm (Holdings) plc

      6-K - TC BioPharm (Holdings) plc (0001872812) (Filer)

      2/10/25 4:05:27 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by TC BioPharm (Holdings) plc

      6-K - TC BioPharm (Holdings) plc (0001872812) (Filer)

      1/8/25 4:16:27 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Randall Diana Elizabeth bought $350,000 worth of Ordinary Shares [ADS] (70,000 units at $5.00)

      4 - TC BioPharm (Holdings) plc (0001872812) (Issuer)

      1/11/23 4:29:05 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Randall Mark Edward bought $350,000 worth of Ordinary Shares [ADS] (70,000 units at $5.00) (Amendment)

      4/A - TC BioPharm (Holdings) plc (0001872812) (Issuer)

      1/11/23 4:09:21 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Randall Kenneth Edward bought $350,000 worth of Ordinary Shares [ADS] (70,000 units at $5.00) (Amendment)

      4/A - TC BioPharm (Holdings) plc (0001872812) (Issuer)

      1/11/23 3:59:36 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCBP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TCBP Announces Transition from Nasdaq to OTC Markets

      EDINBURGH, Scotland, March 21, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company"), (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on March 20, 2025, it received notice that the Nasdaq Hearings Panel had determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of $1.00 per share. Management is currently working on an appeal with Nasdaq.

      3/21/25 10:45:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead

      The company is expected to reduce core operational burn by 55% when compared to 2024EDINBURGH, Scotland, March 18, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced initiatives to outsource several functions, moving to a more decentralized model, resulting in reduction in its workforce and creating a leaner and more agile organization as part of the company's strategic developmental plan. 

      3/18/25 8:03:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company

      FDA-approved product in a multi-billion-dollar marketRevenue generation projected in 2025EDINBURGH, Scotland, March 5, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company focused on commercializing novel therapies for decreasing intraocular pressure in patients with glaucoma and ocular hypertension.

      3/5/25 8:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCBP
    Financials

    Live finance-specific insights

    See more
    • /C O R R E C T I O N -- TC BioPharm/

      In the news release, TCBP Issues 25% Stock Dividend, issued 30-Dec-2024 by TC BioPharm over PR Newswire, we are advised by the company that in the fourth paragraph, both instances of "January 8" should instead read "January 7". The complete, corrected release follows: TCBP Issues 25% Stock Dividend EDINBURGH, Scotland, Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally approved the recently announced 25% stock dividend.

      12/30/24 10:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCBP Issues 25% Stock Dividend

      EDINBURGH, Scotland, Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally approved the recently announced 25% stock dividend. Today, TC BioPharm declared that last week's proposed special stock dividend was formally approved at today's General Meeting of the Company. The special dividend of 0.25 American Depositary Shares ("ADSs") for every 1 ADS he

      12/30/24 10:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend

      EDINBURGH, Scotland, Dec. 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its Board of Directors has approved a special dividend to its shareholders of 0.25 American Depositary Shares ("ADSs") for every 1 ADS held by shareholders, pending shareholder approval. The Company intends to hold a general meeting of shareholders ("GM") at 2:00 p.m. (UK time) on Monday, December 30, 2024, at The Seafield Arms Hotel, 17-19 Seafield St, Cullen, Buckie AB56 4SH, Scotland, United Kingdom.

      12/18/24 8:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCBP
    Leadership Updates

    Live Leadership Updates

    See more
    • TC BioPharm Announces Dr. Mike Leek as Chief Technology Officer

      EDINBURGH, Scotland, Feb. 23, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Dr. Michael Leek to the position of Chief Technology Officer. Dr. Leek resumes operational duties as CTO after stepping down as executive chairman of the board. With more than 35 years experience in cell-based research and development, Co-founder, Michael Leek, Ph.D., had previously served as TC BioPharm's Exec

      2/23/23 8:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TC BioPharm Announces New Chair of the Board, Arlene Morris

      EDINBURGH, Scotland, Feb. 14, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Arlene M. Morris to the position of Chair of the Board. Ms. Morris has held a seat on the TC BioPharm board as an independent director since 2022. An accomplished biotech executive and board member, with many years of experience, Ms. Morris has a proven track record of evolving businesses and en

      2/14/23 8:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division

      Will oversee expansion of U.S. FDA Clinical TrialsEDINBURGH, Scotland, Jan. 30, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Bree Harlin as Chief Clinical Officer (CCO), effective immediately. Ms. Harlin brings more than twenty years of experience in research, oncology and clinical stage drug development to TC BioPharm.  Most recently she was with Loxo at Lilly, where

      1/30/23 8:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc

      SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

      11/14/24 4:41:42 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc (Amendment)

      SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

      2/14/24 2:34:04 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc (Amendment)

      SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

      1/29/24 9:16:48 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care